

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

Metadol Liquid, Methadose, and Compounded Methadone in Patients Using Opioid Agonist Therapy: Comparative Clinical Effectiveness and Guidelines

Service Line: Rapid Response Service
Version: 1.0
Publication Date: April 12, 2018
Report Length: 7 Pages

Authors: Casey Gray, Sarah Visintini

Cite As: *Metadol liquid, methadose, and compounded methadone in patients using opioid agonist therapy: comparative clinical effectiveness*. Ottawa: CADTH; 2018 Apr. (CADTH rapid response report: summary of abstracts).

Acknowledgments:

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Research Questions

1. What is the comparative clinical effectiveness of metadol liquid or methadose versus compounded methadone in patients using opioid agonist therapy?
2. What are the evidence-based guidelines on the use of metadol liquid or methadose over compounded methadone in patients using opioid agonist therapy?

Key Findings

No literature was identified on the clinical effectiveness of metadol liquid or methadose versus compounded methadone in patients using opioid agonist therapy. Moreover, no evidence-based guidelines were identified on the use of metadol liquid or methadose over compounded methadone in patients using opioid agonist therapy.

Methods

A limited literature search was conducted on key resources including Medline (in Ovid), PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 01, 2008 and March 28, 2018. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	Patients using opioid agonist therapy (OAT)
Intervention	Q1: Compounded methadone Q2: Compounded methadone
Comparator	Q1: Metadol liquid or methadose Q2: Metadol liquid or methadose
Outcomes	Comparative clinical effectiveness (benefit/harm), safety, cost, pharmacokinetic outcomes (e.g., does one medication wear off sooner), guidelines
Study Designs	Health technology assessments, systematic reviews, and meta-analyses, randomized controlled trials, non-randomized studies, and evidence-based guidelines

Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

No health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, or non-randomized studies regarding the comparative clinical effectiveness of metadol liquid or methadose versus compounded methadone in patients using opioid agonist therapy were identified. No evidence-based guidelines were identified regarding the use of metadol liquid or methadose over compounded methadone in patients using opioid agonist therapy.

References of potential interest are provided in the appendix.

Overall Summary of Findings

No relevant literature was found regarding the comparative clinical effectiveness of metadol liquid or methadose versus compounded methadone in patients using opioid agonist therapy. Moreover, no evidence-based guidelines were identified regarding the use of metadol liquid or methadose over compounded methadone in patients using opioid agonist therapy, therefore no summary can be provided.

References Summarized

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

No literature identified.

Randomized Controlled Trials

No literature identified.

Non-Randomized Studies

No literature identified.

Guidelines and Recommendations

No literature identified.

Appendix — Further Information

Previous CADTH Reports

1. Buprenorphine/naloxone versus methadone for the treatment of opioid dependence: a review of comparative clinical effectiveness, cost-effectiveness and guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Sep 2. [cited 2018 Apr 10]. (CADTH Rapid response reports: Peer-reviewed summary with critical appraisal). Available from: <https://www.cadth.ca/buprenorphinenaloxone-versus-methadone-treatment-opioid-dependence-review-comparative-clinical>
2. Narcotics, benzodiazepines, stimulants, and gabapentin: policies, initiatives, and practices across Canada [Internet]. Ottawa: CADTH; 2014 Oct. [cited 2018 Apr 10]. (Environmental scan; no.45). Available from: <https://www.cadth.ca/narcotics-benzodiazepines-stimulants-and-gabapentin-policies-initiatives-and-practices-across-canada>
Note: Mention methadone programs in Canada
3. Treatment for opioid dependency: a review of guidelines [Internet]. Ottawa: CADTH; 2012 Sep. [cited 2018 Apr 10]. (CADTH Rapid response reports: summary with critical appraisal). Available from: <https://www.cadth.ca/treatment-opioid-dependency-review-guidelinesk>

Additional References – Related to BC Regulatory Changes

4. Klimas J, Wood E, Nosova E, Milloy MJ, Kerr T, Hayashi K. Prevalence of heavy alcohol use among people receiving methadone following change to methadose. *Subst Use Misuse*. 2018 Jan 28;53(2):270-5.
[PubMed: PM28605308](#)
5. Socias ME, Wood E, McNeil R, Kerr T, Dong H, Shoveller J, et al. Unintended impacts of regulatory changes to British Columbia Methadone Maintenance Program on addiction and HIV-related outcomes: An interrupted time series analysis. *Int J Drug Policy*. 2017 Jul;45:1-8, 2017 Jul:-8.
[PubMed: PM28454044](#)
6. Greer AM, Hu S, Amlani A, Moreheart S, Sampson O, Buxton JA. Patient perspectives of methadone formulation change in British Columbia, Canada: outcomes of a provincial survey. *Subst Abuse Treat Prev Policy*. 2016 Jan 14;11:3, 2016 Jan 14.
[PubMed: PM26762162](#)
7. Markwick N, McNeil R, Anderson S, Small W, Kerr T. Communicating risk in the context of methadone formulation changes: A qualitative study of overdose warning posters in Vancouver, Canada. *Int J Drug Policy*. 2016 Jan;27:178-81, 2016 Jan:-81.
[PubMed: PM26644025](#)
8. McNeil R, Kerr T, Anderson S, Maher L, Keewatin C, Milloy MJ, et al. Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study. *Soc Sci Med*. 2015 May;133:168-76, 2015 May:-76.
[PubMed: PM25875323](#)

Evidence-Based Guidelines – Compounded Methadone Only

9. Bruneau et al. Management of opioid use disorders: a national clinical practice guideline [Internet]. CMAJ 2018 March 5 [cited 2018 Apr 10];190:E247-57. Available from: <http://www.cmaj.ca/content/cmaj/190/9/E247.full.pdf>
10. A Guideline for the clinical management of opioid use disorder [Internet]. Vancouver (BC): British Columbia Centre on Substance Use and B.C. Ministry of Health; 2017 [cited 2018 Apr 10]. Available from: http://www.bccsu.ca/wp-content/uploads/2017/06/BC-OUD-Guidelines_June2017.pdf
11. Management of Substance Use Disorders Work Group. VA/DoD clinical practice guideline for the management of substance use disorders [Internet]. Version 3.0. Washington (DC): Department of Veterans Affairs, Department of Defense; 2015 Dec. [cited 2018 Apr 10]. 169 p. <https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRRevised22216.pdf>
12. Chou R, Cruciani RA, Fiellin DA, Compton P, Farrar JT, Haigney MC, Inturrisi C, Knight JR, Otis-Green S, Marcus SM, Mehta D, Meyer MC, Portenoy R, Savage S, Strain E, Walsh S, Zeltzer L, American Pain Society, Heart Rhythm Society. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain [Internet]. 2014 Apr [cited 2018 Apr 10];15(4):321-37. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/24685458?dopt=Abstract>
13. Methadone maintenance treatment: program standards and clinical guidelines [Internet]. Toronto (ON): College of Royal Physicians & Surgeons of Ontario; 2011 [cited 2018 Apr 10]. Available from: <http://www.cpso.on.ca/uploadedFiles/members/MMT-Guidelines.pdf>
14. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Ann Intern Med. 2009 Mar 17;150(6):387-95. [PubMed: PM19153406](https://pubmed.ncbi.nlm.nih.gov/19153406/)

Clinical Practice Guidelines – Methodology Uncertain

15. Methadone and buprenorphine: clinical practice guideline for opioid use disorder [Internet]. Vancouver (BC): College of Physicians and Surgeons of British Columbia. 2016 [cited 2018 Apr 10]. Available from: <https://www.divisionsbc.ca/CMSMedia/Divisions/DivisionCatalog-nanaimo/Documents/Substance%20Use/Resources/Opiod/MBMT-Clinical-Practice-Guideline.pdf>
16. Principles for the provision of opioid dependence treatment by Manitoba pharmacists [Internet]. Winnipeg (MB): College of Pharmacists of Manitoba; 2016 [cited 2018 Apr 10]. Available from: [https://cphm.ca/uploaded/web/Guidelines/Principles%20for%20the%20Provision%20of%20Opioid%20Dependence%20Treatment%20by%20Manitoba%20Pharmacists%20final%20-%20October%2017%2C%202016\).pdf](https://cphm.ca/uploaded/web/Guidelines/Principles%20for%20the%20Provision%20of%20Opioid%20Dependence%20Treatment%20by%20Manitoba%20Pharmacists%20final%20-%20October%2017%2C%202016).pdf)

17. Alberta methadone maintenance treatment: standards and guidelines for dependence [Internet]. Edmonton (AB): College of Physicians and Surgeons of Alberta; 2014 [cited 2018 Apr 10]. Available from: <http://cpsa.ca/wp-content/uploads/2015/06/alberta-mmt-standards-guidelines.pdf>
18. ODT guidelines: medication-assisted treatment for opioid dependence: guidelines for pharmacists and pharmacy technicians [Internet]. Edmonton (AB): Alberta College of Pharmacists; 2014 [cited 2018 Apr 10]. Available from: <https://pharmacists.ab.ca/system/files/ODTGuidelines.pdf>

ODT guidelines addendum: compounding methadone [Internet]. Edmonton (AB): Alberta College of Pharmacists; 2014 [cited 2018 Apr 10]. Available from: <https://pharmacists.ab.ca/sites/default/files/CompoundingMethadoneAddendum.pdf>
19. Saskatchewan methadone guidelines for the treatment of opioid addiction/dependence [Internet]. Saskatoon (SK): College of Physicians and Surgeons of Saskatchewan; 2008 [cited 2018 Apr 10]. Available from: [http://www.cps.sk.ca/imis/Documents/Programs%20and%20Services/Methadone/Methadone%20for%20Pain%20Guidelines%20-%20Sask\(2\).pdf](http://www.cps.sk.ca/imis/Documents/Programs%20and%20Services/Methadone/Methadone%20for%20Pain%20Guidelines%20-%20Sask(2).pdf)